Monday, June 06, 2011 10:57:28 AM
MCET granted another 2 patents. Yet to be PRed.
MCET had the exclusive licence for the 2 patents. Similar to the arrangement for the patent granted just PRed last week.
See photos below for confirmation. Can check out USPTO to confirm for yourself.
1) POLYANHYDRIDES WITH THERAPEUTICALLY USEFUL DEGRADATION PRODUCTS
Publication No.: 20100074937
Notice of Allowance Granted (i.e. patent will be issued once all fees paid up): 11 May 2011
An aromatic polyanhydride comprising a repeating unit having the structure ##STR00001## is disclosed, wherein Ar and R are selected so that the aromatic polyanhydride hydrolyzes to form a therapeutic salicylate, another non-steroidal anti-inflammatory, an antifibrotic aminobenzoate, or a vasoconstricting phenylethanolamine. Implantable medical devices, such as scaffolding implants for tissue reconstruction, drug delivery systems prepared from the aromatic polyanhydrides, as well as therapeutic dosage forms and treatment methods are also disclosed.
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=20100074937&OS=20100074937&RS=20100074937
2) Medical devices employing novel polymers
Publication No.: 20060188546
Notice of Allowance Granted : 21 Mar 2011
Medical devices with at least one surface comprising a polymer or polymers on the surface are provided. The polymer or polymers are capable of breaking down (e.g., including, but not limited to, hydrolyzing) in the physiologic milieu to form an active agent or agents under physiologic conditions, and can contain other active agents dispersed within or appended to the polymer matrix. Methods of delivering an active agent to an interior surface of a vein or artery are also provided.
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=2&f=G&l=50&co1=AND&d=PG01&s1=20060188546&OS=20060188546&RS=20060188546
About Xenogenics Corporation
Xenogenics Corporation is a development-stage medical device company focused on the design of next-generation bioabsorbable stents for interventional cardiology and peripheral vessel applications. Xenogenics is a majority owned subsidiary of MultiCell Technologies, Inc. (OTC Bulletin Board: MCET).
MultiCell Technologies increased its ownership position in Xenogenics Corporation to 91.72% as a result of providing the acquisition financing.
http://ih.advfn.com/p.php?pid=nmona&article=44842447
MCET had the exclusive licence for the 2 patents. Similar to the arrangement for the patent granted just PRed last week.
See photos below for confirmation. Can check out USPTO to confirm for yourself.
1) POLYANHYDRIDES WITH THERAPEUTICALLY USEFUL DEGRADATION PRODUCTS
Publication No.: 20100074937
Notice of Allowance Granted (i.e. patent will be issued once all fees paid up): 11 May 2011
An aromatic polyanhydride comprising a repeating unit having the structure ##STR00001## is disclosed, wherein Ar and R are selected so that the aromatic polyanhydride hydrolyzes to form a therapeutic salicylate, another non-steroidal anti-inflammatory, an antifibrotic aminobenzoate, or a vasoconstricting phenylethanolamine. Implantable medical devices, such as scaffolding implants for tissue reconstruction, drug delivery systems prepared from the aromatic polyanhydrides, as well as therapeutic dosage forms and treatment methods are also disclosed.
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=20100074937&OS=20100074937&RS=20100074937
2) Medical devices employing novel polymers
Publication No.: 20060188546
Notice of Allowance Granted : 21 Mar 2011
Medical devices with at least one surface comprising a polymer or polymers on the surface are provided. The polymer or polymers are capable of breaking down (e.g., including, but not limited to, hydrolyzing) in the physiologic milieu to form an active agent or agents under physiologic conditions, and can contain other active agents dispersed within or appended to the polymer matrix. Methods of delivering an active agent to an interior surface of a vein or artery are also provided.
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=2&f=G&l=50&co1=AND&d=PG01&s1=20060188546&OS=20060188546&RS=20060188546
About Xenogenics Corporation
Xenogenics Corporation is a development-stage medical device company focused on the design of next-generation bioabsorbable stents for interventional cardiology and peripheral vessel applications. Xenogenics is a majority owned subsidiary of MultiCell Technologies, Inc. (OTC Bulletin Board: MCET).
MultiCell Technologies increased its ownership position in Xenogenics Corporation to 91.72% as a result of providing the acquisition financing.
http://ih.advfn.com/p.php?pid=nmona&article=44842447
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
